Direxion Daily S&P Biotech Bull 3X ETF

LABU

Market cap $617M

LABU Hedge Fund Activity: Q1 2026 in Review

33 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Direxion Daily S&P Biotech Bull 3X ETF (LABU) for Q1 2026, worth a combined $56.7M — up 28% from $44.4M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of LABU and 6 opened new positions — a net loss of 6 holders — while 11 trimmed existing stakes and 10 added.

The largest buyer was Jump Financial, opening a new position worth an estimated $9.13M. The largest seller was Renaissance Technologies, exiting entirely with an estimated $3.65M sold.

• 33 institutional investors held Direxion Daily S&P Biotech Bull 3X ETF (LABU) as of Q1 2026, down from 40 in Q4 2025.
• Funds reported $56.7M of Direxion Daily S&P Biotech Bull 3X ETF stock for Q1 2026, up 28% quarter-over-quarter.
• 6 funds opened new Direxion Daily S&P Biotech Bull 3X ETF positions in Q1 2026 and 12 closed out, a net change of -6 holders.
• The largest Direxion Daily S&P Biotech Bull 3X ETF buyer in Q1 2026 was Jump Financial, an estimated $9.13M added.
• The largest Direxion Daily S&P Biotech Bull 3X ETF seller in Q1 2026 was Renaissance Technologies, an estimated $3.65M sold.

Based on aggregated 13F filings for Q1 2026.